134 related articles for article (PubMed ID: 11450666)
1. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Sargent DJ; Niedzwiecki D; O'Connell MJ; Schilsky RL
N Engl J Med; 2001 Jul; 345(2):144-5; author reply 146. PubMed ID: 11450666
[No Abstract] [Full Text] [Related]
2. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Ledermann JA; Leonard P; Seymour M
N Engl J Med; 2001 Jul; 345(2):145-6. PubMed ID: 11450667
[No Abstract] [Full Text] [Related]
3. Researchers urge caution with standard regimen for metastatic colorectal cancer.
Traynor K
Am J Health Syst Pharm; 2001 Jul; 58(13):1180. PubMed ID: 11449873
[No Abstract] [Full Text] [Related]
4. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Erlichman C; Goldberg RM; O'Connell MJ
N Engl J Med; 2001 Jan; 344(4):305; author reply 306-7. PubMed ID: 11191661
[No Abstract] [Full Text] [Related]
5. Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer.
Fisher MD
Clin Colorectal Cancer; 2001 Aug; 1(2):82-4. PubMed ID: 12445364
[No Abstract] [Full Text] [Related]
6. Toxicity of irinotecan in patients with colorectal cancer.
Van Cutsem E; Douillard JY; Köhne CH
N Engl J Med; 2001 Nov; 345(18):1351-2. PubMed ID: 11794165
[No Abstract] [Full Text] [Related]
7. Adjuvant irinotecan regimens in combination with infusional 5-fluorouracil/leucovorin fail to improve outcomes in surgically resected colorectal cancer.
Tyagi P
Clin Colorectal Cancer; 2005 Jul; 5(2):86-8. PubMed ID: 16098248
[No Abstract] [Full Text] [Related]
8. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Vaiani M; Trippoli S; Messori A
N Engl J Med; 2001 Jan; 344(4):305-6; author reply 306-7. PubMed ID: 11191660
[No Abstract] [Full Text] [Related]
9. [Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].
Motomura S
Nihon Rinsho; 2003 Sep; 61 Suppl 7():360-3. PubMed ID: 14574913
[No Abstract] [Full Text] [Related]
10. N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.
Goldberg RM
Clin Colorectal Cancer; 2002 Aug; 2(2):81. PubMed ID: 12453321
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
12. [Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].
Klautke G; Fietkau R
Strahlenther Onkol; 2002 Mar; 178(3):163-4. PubMed ID: 11962194
[No Abstract] [Full Text] [Related]
13. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Pignon JP; Ducreux M
N Engl J Med; 2001 Jan; 344(4):306; author reply 306-7. PubMed ID: 11191663
[No Abstract] [Full Text] [Related]
14. Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
Hwang JJ
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):26-34. PubMed ID: 15685831
[TBL] [Abstract][Full Text] [Related]
15. [Capecitabine and irinotecan].
Gasperoni S
Suppl Tumori; 2004; 3(4):S107-8. PubMed ID: 15206231
[No Abstract] [Full Text] [Related]
16. Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
Yao Y; Sun YJ; Zhao H; Guo YW; Lin F; Cai X; Tang XC; Tang LN; Zhang W
Chin Med J (Engl); 2006 Nov; 119(21):1829-33. PubMed ID: 17097039
[No Abstract] [Full Text] [Related]
17. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin.
Bleiberg H; Di Leo A
J Clin Oncol; 2002 Feb; 20(4):1145-6. PubMed ID: 11844840
[No Abstract] [Full Text] [Related]
18. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
[TBL] [Abstract][Full Text] [Related]
19. Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.
Chico IM; Pazdur R
Clin Colorectal Cancer; 2002 May; 2(1):11-2. PubMed ID: 12453329
[No Abstract] [Full Text] [Related]
20. Moving beyond fluorouracil for colorectal cancer.
Mayer RJ
N Engl J Med; 2000 Sep; 343(13):963-4. PubMed ID: 11006373
[No Abstract] [Full Text] [Related]
[Next] [New Search]
